Silkworm expression system as a platform technology in life science

Many recombinant proteins have been successfully produced in silkworm larvae or pupae and used for academic and industrial purposes. Several recombinant proteins produced by silkworms have already been commercialized. However, construction of a recombinant baculovirus containing a gene of interest requires tedious and troublesome steps and takes a long time (3–6 months). The recent development of a bacmid, Escherichia coli and Bombyx mori shuttle vector, has eliminated the conventional tedious procedures required to identify and isolate recombinant viruses. Several technical improvements, including a cysteine protease or chitinase deletion bacmid and chaperone-assisted expression and coexpression, have led to significantly increased protein yields and reduced costs for large-scale production. Terminal N-acetyl glucosamine and galactose residues were found in the N-glycan structures produced by silkworms, which are different from those generated by insect cells. Genomic elucidation of silkworm has opened a new chapter in utilization of silkworm. Transgenic silkworm technology provides a stable production of recombinant protein. Baculovirus surface display expression is one of the low-cost approaches toward silkworm larvae-derived recombinant subunit vaccines. The expression of pharmaceutically relevant proteins, including cell/viral surface proteins, membrane proteins, and guanine nucleotide-binding protein (G protein) coupled receptors, using silkworm larvae or cocoons has become very attractive. Silkworm biotechnology is an innovative and easy approach to achieve high protein expression levels and is a very promising platform technology in the field of life science. Like the “Silkroad,” we expect that the “Bioroad” from Asia to Europe will be established by the silkworm expression system

Potential of DIVA vaccines for Fish

The expanding aquaculture industry continues to encounter major challenges from highly contagious viruses. Control and eradication measures for lethal and economically damaging notifiable viral diseases involve ‘stamping out’ policies and surveillance strategies. Mass-culling of stock and restricted movement of fish and fish products, used to control the spread of notifiable diseases, has considerable impacts on the trade of fish products. Although effective, these measures are expensive and ethically complex and could possibly be reduced by emulating innovative vaccination strategies used by the terrestrial livestock industry. DIVA (differentiating infected from vaccinated animal) strategies provide a basis to vaccinate and contain disease outbreaks without compromising ‘disease-free’ status, as antibodies induced during infection can be used to distinguish from those induced by vaccination. The potential and feasibility of DIVA vaccination in aquaculture is explored here with reference to DIVA strategies applied in higher vertebrates. Three economically important notifiable viruses, causing major problems in three different cultured fish industries, are considered. The increased availability and application of sophisticated biotechnology tools has enabled improved prophylaxis and serological diagnosis for control of viral haemorrhagic septicaemia in rainbow trout, infectious salmon anaemia in Atlantic salmon and koi herpesvirus disease in carp. Improving the specificity of serological diagnostics in aquaculture in conjunction with suitable vaccines could enable the application of DIVA strategies, but the immunological variation between different fish species and contrasting pathobiological characteristics of different viruses determines the feasibility and potential of such DIVA approaches for aquaculture industries